Alto Neuroscience ANRO ALTO-203 — Direct external program expenses:
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's alto-203 — direct external program expenses:.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's ALTO-203 — direct external program expenses:?
- Alto Neuroscience (ANRO) reported ALTO-203 — direct external program expenses: of $6K in Q1 2026.
- How has Alto Neuroscience's ALTO-203 — direct external program expenses: changed year-over-year?
- Alto Neuroscience's ALTO-203 — direct external program expenses: decreased by 99.2% year-over-year, from $737K to $6K.
- What is the long-term trend for Alto Neuroscience's ALTO-203 — direct external program expenses:?
- Over 2 years (2023 to 2025), Alto Neuroscience's ALTO-203 — direct external program expenses: has grown at a 170.1% compound annual growth rate (CAGR), from $222K to $1.62M.
- What does ALTO-203 — direct external program expenses: mean?
- This metric represents the direct external costs incurred for the research and development of the specific clinical-stage pharmaceutical asset. It captures expenditures related to outsourced clinical trials, contract research organizations, and manufacturing activities dedicated to advancing this program through the development pipeline. Monitoring these costs provides insight into the capital intensity and progress of individual drug candidates within the company's portfolio.